Alyeska Investment Group
SPRO icon

Alyeska Investment Group’s Spero Therapeutics SPRO Stock Holding History

Alyeska Investment Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-49,602
Closed -$730K – 827
2021
Q1 		$730K Hold
49,602
– – 0.01% 633
2020
Q4 		$962K Sell
49,602
-50,398
-50% -$786K 0.01% 418
2020
Q3 		$1.12M Buy
+100,000
New +$1.18M 0.02% 382

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Alyeska Investment Group's SPRO Position: Q2 2021 in Review

Alyeska Investment Group sold out of Spero Therapeutics (SPRO) in Q2 2021, closing a stake of 49,602 shares — an estimated $730K sold.

Alyeska Investment Group first reported a position in SPRO in Q3 2020 and held it in 3 quarters. The position peaked at $1.12M in Q3 2020. 88 funds tracked by Wall St. Rank hold SPRO as of Q2 2021.

  • Alyeska Investment Group reported no remaining Spero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 49,602 Spero Therapeutics shares in Q2 2021, an estimated $730K.
  • Alyeska Investment Group first reported a position in Spero Therapeutics in Q3 2020 and held it in 3 quarters.
  • Alyeska Investment Group's Spero Therapeutics position peaked at $1.12M in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.